US · Healthcare · Medical Devices
EPS came in at 1.34 against a street estimate of 1.21 — a beat of 10.7%.
Analysts rate GE HealthCare Technologies Inc. a buy (16 buy, 6 hold, 0 sell out of 22) with an average price target of $87.50.
CONFIDENT GE Healthcare delivered strong third-quarter growth, margin expansion and cash generation, raising 2026 guidance. AIS and PDx remained healthy, while PCS recovered operationally despite a tougher comparison ahead. Q3 FY26 Management said China is recovering with better activity and tender consistency, but significant work remains; most reported growth was FX-driven. Analysts focused on capital spending, backlog timing, Picado and Sofie, China, memory-chip supply, PCS recovery and 2027 margins. Management emphasized resilient demand, improved execution and confidence in continued growth, while acknowledging tariff and comparison risks. 2026-10-28…
Full summary in the app.
| Fund | Stake |
|---|---|
| Dodge & Cox | 8.37% |
| BlackRock Inc | 8.29% |
| Vanguard Capital Management, LLC | 6.57% |
| State Street Corp | 4.61% |
| Vanguard Portfolio Management, LLC | 4.48% |
| Amvescap Plc. | 4.05% |
| Harris Associates L.P. | 3.39% |
| Barrow Hanley Mewhinney & Strauss LLC | 2.98% |
| Document | Date |
|---|---|
| Board / officer change · Q4 2026 OTHER NOTABLE POINTS • Taha Kass-Hout will resign as GE HealthCare’s Chief Science and Technology Officer. • His last day at the company will be Dec | 2026-11-05 |
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $5,513 million, up from $5,143 million in the third quarter of 2025. • Nine-month 2026 revenue was | 2026-10-28 |
| Results announced · Q4 2026 HEADLINE NUMBERS • GE HealthCare reported third-quarter 2026 revenue of $5.5 billion, up 7.2%; organic revenue growth was 6.2%. • Organic orders gre | 2026-10-28 |
| Board / officer change · Q3 2026 GE HEALTHCARE TECHNOLOGIES INC. - DOCUMENT SUMMARY OTHER NOTABLE POINTS • Director Appointment: Pascal Desroches appointed to the Board of Directors | 2026-09-22 |
| Board / officer change · Q3 2026 GE HEALTHCARE TECHNOLOGIES INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • New CFO appointment effective September 14, 2026 • Total compensation package: | 2026-08-18 |
| Quarterly report · Q2 2026 GE HEALTHCARE TECHNOLOGIES INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Total revenues Q2 2026: $5,295 million (vs. $5,007 million Q2 2025) — up 5 | 2026-07-29 |
| Reg FD disclosure · Q3 2026 GE HEALTHCARE TECHNOLOGIES INC. — FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Company restructured its operating segments in Q2 2026, combining | 2026-07-29 |
| Results announced · Q3 2026 GE HEALTHCARE Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total revenue of $5.3 billion, up 5.7% year-over-year; organic revenue growth of 3.5% • Ne | 2026-07-29 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.04 / share ex-date Oct 23, 2026 · pay Nov 13, 2026 | 2026-10-23 |
| Dividend | $0.04 / share ex-date Jul 24, 2026 · pay Aug 14, 2026 | 2026-07-24 |
| Dividend | $0.04 / share ex-date Apr 2, 2026 · pay May 15, 2026 | 2026-04-02 |
| Dividend | $0.04 / share ex-date Jan 9, 2026 · pay Feb 13, 2026 | 2026-01-09 |
| Dividend | $0.04 / share ex-date Oct 24, 2025 · pay Nov 14, 2025 | 2025-10-24 |
| Announcement | Date |
|---|---|
| Issued $1.25B senior notes to finance previously announced Intelerad acquisition GE HealthCare Technologies issued $1.25 billion in senior notes to finance its acquisition of Intelerad Medical Systems. The company sold two tranches: $600 million of 4.150% notes due in 20 | 2025-12-15 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for GE HealthCare Technologies Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.